Yahong Pharma released its 2023 annual report: the global phase III clinical trial of its core product APL-1702 was successfully accepted by the domestic NDA of APL-1706 The "hematopoiesis" of the specialist commercialization team has begun to bear fruit
In 2022, the global lignin product market will reach 7.296 billion yuan (RMB), and the Chinese lignin product market will reach xx billion yuan. The report expects that by 2028...